2025 Q2 Portfolio Activity
In 2025 Q2, Camber Capital Management LP maintained a portfolio of 36 distinct positions. The most significant new addition was ICON PLC, now representing 4.10% of the total fund value. They heavily accumulated shares in BIOMARIN PHARMACEUTICAL INC, increasing the position by 20.0%. Conversely, Camber Capital Management LP completely exited their position in SPDR SER TR.
Position History
hover any row below to update
Loading…
Total Positions
36
Quarter
2025 Q2
Top Holding
SPY (29.0%)
Top 10 Concentration
79.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-36 of 36
Camber Capital Management LP Full Holdings List — 2025 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
SPY
PUT
SPDR S&P 500 ET...
|
PUT Option | 29.00% | 29.81% |
#1
Prev: #1
|
6.0 |
—
|
-1,000,000 | -66.7% |
P
S
|
500,000 | $308,925,000 |
$303.09
+146.0%
|
2011 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | ||
|
ZBH
ZIMMER BIOMET H...
|
Healthcare | 8.56% | 9.05% |
#2
Prev: #2
|
4.9 |
—
|
-1,250,000 | -55.6% |
P
S
|
1,000,000 | $91,210,000 | 2010 Q4 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
BAX
BAXTER INTL INC
|
Healthcare | 8.10% | 6.99% |
#3
Prev: #3
|
4.2 |
—
|
-2,900,000 | -50.4% |
P
S
|
2,850,000 | $86,298,000 | 2023 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
HUM
HUMANA INC
|
Healthcare | 6.89% | 6.81% |
#4
Prev: #4
|
3.3 |
—
|
-425,000 | -58.6% |
P
S
|
300,000 | $73,344,000 | 2010 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
CVS
CVS HEALTH CORP
|
Healthcare | 6.80% | 5.42% |
#5
2
Prev: #7
|
3.2 |
—
|
-1,200,000 | -53.3% |
P
S
|
1,050,000 | $72,429,000 | 2009 Q4 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
GMED
GLOBUS MED INC
|
Healthcare | 4.43% | 3.25% |
#6
2
Prev: #8
|
1.8 |
—
|
-450,000 | -36.0% |
P
S
|
800,000 | $47,216,000 | 2023 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
ICLR
ICON PLC
|
Healthcare | 4.10% | — |
#7
Prev: #—
|
5.1 |
—
|
300,000 | — |
NEW
|
300,000 | $43,635,000 | 2025 Q2 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 4.05% | 1.94% |
#8
6
Prev: #14
|
1.6 |
—
|
-100,000 | -28.6% |
P
S
|
250,000 | $43,150,000 | 2019 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
MRK
MERCK & CO INC
|
Healthcare | 3.72% | — |
#9
Prev: #—
|
5.0 |
—
|
500,000 | — |
NEW
|
500,000 | $39,580,000 | 2013 Q4 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
GSK
CALL
GSK PLC
|
CALL Option | 3.60% | 1.38% |
#10
7
Prev: #17
|
2.4 |
—
|
no change | no change |
P
S
|
1,000,000 | $38,400,000 | 2013 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
PFE
PFIZER INC
|
Healthcare | 3.41% | 2.25% |
#11
1
Prev: #12
|
1.4 |
—
|
-1,000,000 | -40.0% |
P
S
|
1,500,000 | $36,360,000 | 2010 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 3.10% | 1.26% |
#12
6
Prev: #18
|
3.7 |
—
|
100,000 | 20.0% |
P
S
|
600,000 | $32,982,000 | 2020 Q3 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
UNH
UNITEDHEALTH GR...
|
Healthcare | 2.93% | — |
#13
Prev: #—
|
4.7 |
—
|
100,000 | — |
NEW
|
100,000 | $31,197,000 | 2009 Q4 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
VTRS
VIATRIS INC
|
Healthcare | 2.31% | 2.32% |
#14
3
Prev: #11
|
0.9 |
—
|
-4,750,000 | -63.3% |
P
S
|
2,750,000 | $24,557,500 | 2020 Q4 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
BKD
BROOKDALE SR LI...
|
Healthcare | 1.40% | 1.39% |
#15
1
Prev: #16
|
0.6 |
—
|
-4,100,000 | -65.6% |
P
S
|
2,150,000 | $14,964,000 | 2015 Q4 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
ZIMV
ZIMVIE INC
|
Unknown | 1.40% | 0.72% |
#16
7
Prev: #23
|
1.1 |
—
|
-285,000 | -15.1% |
P
S
|
1,600,000 | $14,960,000 | 2022 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
APLS
APELLIS PHARMAC...
|
Healthcare | 1.38% | — |
#17
Prev: #—
|
4.1 |
—
|
850,000 | — |
NEW
|
850,000 | $14,713,500 | 2025 Q2 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
MYGN
MYRIAD GENETICS...
|
Healthcare | 1.00% | 0.74% |
#18
4
Prev: #22
|
0.9 |
—
|
-350,000 | -14.9% |
P
S
|
2,000,000 | $10,620,000 | 2010 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
EVH
EVOLENT HEALTH ...
|
Healthcare | 0.90% | 1.01% |
#19
1
Prev: #20
|
0.4 |
—
|
-2,150,000 | -71.7% |
P
S
|
850,000 | $9,571,000 | 2022 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
CON
CONCENTRA GROUP...
|
Healthcare | 0.77% | 1.23% |
#20
1
Prev: #19
|
0.3 |
—
|
-1,200,000 | -75.0% |
P
S
|
400,000 | $8,228,000 | 2024 Q3 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
INGN
INOGEN INC
|
Healthcare | 0.64% | 0.25% |
#21
8
Prev: #29
|
1.3 |
—
|
no change | no change |
P
S
|
975,000 | $6,854,250 | 2021 Q4 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
DNLI
DENALI THERAPEU...
|
Healthcare | 0.53% | 0.60% |
#22
3
Prev: #25
|
0.2 |
—
|
-850,000 | -68.0% |
P
S
|
400,000 | $5,596,000 | 2024 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
TBPH
THERAVANCE BIOP...
|
Healthcare | 0.47% | 0.32% |
#23
4
Prev: #27
|
0.2 |
—
|
-550,000 | -55.0% |
P
S
|
450,000 | $4,963,500 | 2021 Q3 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
ANAB
ANAPTYSBIO INC
|
Healthcare | 0.26% | 0.50% |
#24
2
Prev: #26
|
0.1 |
—
|
-625,000 | -83.3% |
P
S
|
125,000 | $2,775,000 | 2024 Q2 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
OSUR
ORASURE TECHNOL...
|
Healthcare | 0.25% | 0.11% |
#25
6
Prev: #31
|
1.1 |
—
|
no change | no change |
P
S
|
900,000 | $2,700,000 | 2015 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
GMAB
GENMAB A/S
|
Healthcare | 0.00% | 0.03% |
Sold All 😨
(Was: #32) |
0.0 |
—
|
-50,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 0.00% | 0.18% |
Sold All 😨
(Was: #30) |
0.0 |
—
|
-300,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
TXG
10X GENOMICS IN...
|
Healthcare | 0.00% | 0.31% |
Sold All 😨
(Was: #28) |
0.0 |
—
|
-1,000,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 0.00% | 0.61% |
Sold All 😨
(Was: #24) |
0.0 |
—
|
-441,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
IONS
IONIS PHARMACEU...
|
Healthcare | 0.00% | 0.78% |
Sold All 😨
(Was: #21) |
0.0 |
—
|
-725,000 | -100.0% |
CLOSED
|
— | $— | 2021 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
SRPT
SAREPTA THERAPE...
|
Healthcare | 0.00% | 1.81% |
Sold All 😨
(Was: #15) |
0.0 |
—
|
-800,000 | -100.0% |
CLOSED
|
— | $— | 2013 Q3 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
QGEN
QIAGEN NV
|
Healthcare | 0.00% | 2.00% |
Sold All 😨
(Was: #13) |
0.0 |
—
|
-1,400,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
CI
THE CIGNA GROUP
|
Healthcare | 0.00% | 2.34% |
Sold All 😨
(Was: #10) |
0.0 |
—
|
-200,000 | -100.0% |
CLOSED
|
— | $— | 2015 Q2 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
PTCT
PTC THERAPEUTIC...
|
Healthcare | 0.00% | 2.72% |
Sold All 😨
(Was: #9) |
0.0 |
—
|
-1,500,000 | -100.0% |
CLOSED
|
— | $— | 2014 Q3 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
XBI
PUT
SPDR SER TR
|
PUT Option | 0.00% | 5.76% |
Sold All 😨
(Was: #6) |
0.0 |
—
|
-2,000,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) | |||
|
PFE
CALL
PFIZER INC
|
CALL Option | 0.00% | 6.12% |
Sold All 😨
(Was: #5) |
0.0 |
—
|
-6,800,000 | -100.0% |
CLOSED
|
— | $— | 2010 Q1 | 13F Filing | 2025-06-30 | 2025-08-14 (Est.) |
Showing 1-36 of 36 holdings